700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Research Article Open Access
Background: People who inject drugs (PWID) are overrepresented in the HCV-infected community. Past Canadian guidelines do not advocate HCV treatment of HIV co-infected PWID, fearing reduced ÃÂÃÂ¸cÃÂcy and recurrent viremia ÃÂÃ ÂÃÂr successful treatment, due to ongoing risk behaviours. These factors may be more prominent among those co-infected with HIV.
Methods: A Retrospective chart review analysis was performed to identify HIV/HCV co-infected individuals who actively injected drugs within 6 months preceding or during HCV treatment. Information regarding ÃÂÃÂÃÂÃÂnÃÂ cÃ ÂÃÂrÃÂcÃÂÃÂrÃ ÂÃÂÃÂcÃÂÃÂ risk behaviours, HCV treatment, and virologic follow-up post-treatment was collected.
Results: We identified 45 HIV/HCV co-infected PWID (mean age 51.9 years, 6.7% female, 57.8% on opiatesubstitution therapy, 66.7% genotype 1, 82.2% treatment naïve, 73.3% on interferon-based therapies, and 1.52 person years of follow-up/subject). Following successful HCV therapy, 3 cases of HCV recurrent viremia were identified
Conclusion: HCV Ã ÂnÃÂ¨ÃÂcÃÂÃ Â½n can be successfully treated in high-risk HIV co-infected individuals. In our unique ÃÂÃÂÃÂ«nÃ ÂÃÂ few cases of recurrent viremia were identified in mediumterm follow-up.
To read the full article Peer-reviewed Article PDF
| Peer-reviewed Full Article
Author(s): Tyler Raycraft Syune Hakobyan Sahand Vafadary Arshia Alimohammadi Ghazal Kiani Jay Shravah Rajvir Shahi and Brian Conway
HCV-infected community, Retrospective analysis, Recurrent viremia, Interferon-based therapies